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Spinal muscular atrophy (SMA) is the most common genetic disease causing infant death,
due to an extended loss of motoneurons. This neuromuscular disorder results from
deletions and/or mutations within the Survival Motor Neuron 1 (SMN1) gene, leading to a
pathological decreased expression of functional full-length SMN protein. Emerging studies
suggest that the small GTPase RhoA and its major downstream effector Rho kinase
(ROCK), which both play an instrumental role in cytoskeleton organization, contribute to
the pathology of motoneuron diseases. Indeed, an enhanced activation of RhoA and ROCK
has been reported in the spinal cord of an SMA mouse model. Moreover, the treatment
of SMA mice with ROCK inhibitors leads to an increased lifespan as well as improved
skeletal muscle and neuromuscular junction pathology, without preventing motoneuron
degeneration. Althoughmotoneurons are the primary target in SMA, an increasing number
of reports show that other cell types inside and outside the central nervous system
contribute to SMA pathogenesis. As administration of ROCK inhibitors to SMA mice was
systemic, the improvement in survival and phenotype could therefore be attributed to
specific effects on motoneurons and/or on other non-neuronal cell types. In the present
review, we will present the various roles of the RhoA/ROCK pathway in several SMA
cellular targets including neurons, myoblasts, glial cells, cardiomyocytes and pancreatic
cells as well as discuss how ROCK inhibition may ameliorate their health and function.
It is most likely a concerted influence of ROCK modulation on all these cell types that
ultimately lead to the observed benefits of pharmacological ROCK inhibition in SMA mice.
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INTRODUCTION
Spinal muscular atrophy (SMA) is a devastating neurodegener-
ative disease, affecting approximately 1:6,000–10,000 live births
per year (Pearn, 1978; Crawford and Pardo, 1996). This autoso-
mal recessive disease, a major inherited cause of infant and child
death (<2 years old), is characterized by the loss of spinal alpha
motoneurons, muscle weakness, atrophy and subsequent paraly-
sis (Crawford and Pardo, 1996). The clinical severity of SMA is
characterized into 4 types: type 1 is the most severe as it primarily
affects newborns, type 2 and type 3 are intermediate forms with a
childhood onset, and type 4 is symptomatically the mildest with
an adult onset (Pearn, 1980; Munsat and Davies, 1992).
SMA is due to homozygous mutations and/or deletions in the
Survival Motor Neuron 1 (SMN1) gene and subsequent reduction
of the SMN protein (Lefebvre et al., 1995). While most species
only have one copy of the gene, humans have two: a telomeric
copy (SMN1) and a duplicated centromeric copy (SMN2), both
located on chromosome 5q13 (Lefebvre et al., 1995; DiDonato
et al., 1997). While SMN1 and SMN2 differ by a few nucleotides,
the C to T substitution in exon 7 of SMN2 is critical (Lorson et al.,
1999). Indeed, it leads to the loss of an exon splicing enhancer
or the gain of an exon splicing silencer that leads to the produc-
tion of a truncated, non-functional SMN protein that lacks exon
7, named SMN7 (Lefebvre et al., 1995; Cartegni and Krainer,
2002; Kashima and Manley, 2003). As a result, SMN7 is the
major product of SMN2 and the number of copies of SMN2 is
linked to the severity of the disease (Lefebvre et al., 1997).
Based on this genetic knowledge, a first mouse model for
SMA was created with a homozygous deletion of the Smn gene
(Schrank et al., 1997). This null mutant, Smn−/−, served to
highlight SMN as a developmentally essential protein since its
complete ablation is embryonic lethal (Schrank et al., 1997)
The heterozygous Smn+/− however, does not develop the typical
histopathological SMA hallmarks and remains at best a hypomor-
phic model for the disease (Schrank et al., 1997; Bowerman et al.,
2014). Thus, several alternate SMA models were eventually cre-
ated in order to more closely mimic the human pathology by
either introducing partially functional human SMN constructs
onto the Smn−/− background or by rendering the endogenous
murine Smn gene similar to the SMN2 copy (reviewed in Bebee
et al., 2012). At present, the most commonly used SMA mod-
els are termed Smn−/−; SMN2 (Hsieh-Li et al., 2000; Monani
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et al., 2000), Smn−/−; SMN2; SMN7/7 (Le et al., 2005) and
Smn2B/− mice (Hammond et al., 2010; Bowerman et al., 2012a)
and range from severe (death within the first post-natal week) to
intermediate phenotypes (average lifespan of 30 days). In spite
of these differences in survival times, all of these models dis-
play spinal cord motoneuron degeneration, muscle atrophy as
well as neuromuscular junction (NMJ) defects and have therefore
been indispensable in our understanding of the disease and in the
evaluation of potential therapeutic approaches.
The SMN protein is found in both the cytoplasm and the
nucleus, where in the latter, it is concentrated in structures
called Cajal bodies and Gemini of coiled bodies (Gems) (Liu and
Dreyfuss, 1996; Carvalho et al., 1999). The best described house-
keeping role for SMN is in the cytoplasmic assembly of small
nuclear ribonucleoproteins (snRNPs), essential components of
the pre-mRNA spliceosome (reviewed in Burghes and Beattie,
2009). Once snRNPs are correctly assembled, the SMN-snRNP
complex is imported in the nucleus where it localizes to Cajal bod-
ies for further processing and maturation (reviewed in Morris,
2008). While splicing defects have been observed in SMA mice
(Zhang et al., 2008; Baumer et al., 2009; Lotti et al., 2012), none
have been qualified as being solely responsible for the pathology
of the disease. Hence the myriad of studies aimed at uncovering
specific neuronal roles for Smn (reviewed in Boyer et al., 2010).
One of these functions is the modulation of the actin cytoskele-
ton, revealed by the initial report that Smn was responsible for
β-actin mRNA localization in motoneuron growth cones (Rossoll
et al., 2003). Subsequent studies in neuronal cells and/or in spinal
cord extracts have further demonstrated a direct or indirect inter-
action between Smn andmolecular modulators of actin dynamics
such as profilin, plastin 3, small Rho GTPases RhoA and Cdc42
as well as Rho kinase (ROCK), a direct downstream effector of
RhoA (Giesemann et al., 1999; Bowerman et al., 2007; Oprea
et al., 2008; Nolle et al., 2011). Interestingly, although the genetic
manipulation of profilin and plastin 3 did not improve the lifes-
pan of SMA mice (Bowerman et al., 2009; Ackermann et al.,
2013), the pharmacological targeting of ROCK (via inhibitors
Y-27632 and Fasudil), a more upstream regulator of actin dynam-
ics, led to a significant increase in survival (Bowerman et al.,
2010, 2012b). The beneficial effect of ROCK inhibition on lifes-
pan was accompanied by an augmentation of muscle fiber size
and an increased morphological maturation of the NMJ, with-
out impacting the number of surviving motoneurons or the
expression level of Smn. While the spinal cord, and more specif-
ically the motoneurons, were the primary therapeutic targets of
ROCK inhibition in SMA mice, the systemic delivery approaches
used in these studies undeniably result in non-neuronal mod-
ulation of the ubiquitously expressed RhoA/ROCK pathway.
Further, although motoneurons are the most vulnerable cell type
in SMA, an increasing number of reports suggest that other
cells and tissues are also affected by loss of SMN (reviewed in
Hamilton and Gillingwater, 2013).
In the present review, we will discuss the potential cellular
targets that may participate in the beneficial effect of ROCK inhi-
bition in SMA mice, To this aim, the role of the RhoA/ROCK
pathway in healthy cells and in SMA pathology will be analyzed
(Figure 1) and we will elaborate on how the systemic modulation
of ROCK could influence these cells and tissues, and potentially
the course of the disease (Figure 2).
NEURONAL CELLS
RhoA/ROCK, NEURONAL CELLS AND SMA
The primary cellular target in SMA is undeniably the spinal
cord motoneuron. In neuronal cells, the modulation of the actin
cytoskeleton by the RhoA/ROCK pathway affects growth, neurite
formation, polarization, branching, regeneration, pathfinding,
guidance and retraction (reviewed in Luo et al., 1997; Govek et al.,
2005). Whether neuronal or non-neuronal, the RhoA/ROCK sig-
naling cascade implicates various downstream effectors such as
cofilin, myosin light chain phosphatase (MYPT), profilin IIa,
Lim kinases (LIMK) and myosin regulatory light chain (MLC)
(reviewed in Schofield and Bernard, 2013).
The first evidence linking SMN and the RhoA/ROCK pathway
was reported in the neuronal-like PC12 cells (Bowerman et al.,
2007). Knocking down Smn in PC12 cells by RNA interference
(RNAi) lead to a reduced differentiation potential, shorter neu-
rites andmore importantly, perturbation of the actin cytoskeleton
and key modulators of actin dynamics. Indeed, in Smn-depleted
PC12 cells, there is an increase in RhoA-GTP, the active form of
the kinase, which is known to inhibit neuronal outgrowth and dif-
ferentiation (reviewed in Hall, 1998; Mueller, 1999). Downstream
effectors of the RhoA/ROCK pathway such as cofilin, MYPT and
profilin IIa (Kimura et al., 1996; Sumi et al., 1999; Da Silva et al.,
2003) are also aberrantly expressed and/or phosphorylated in
Smn-depleted PC12 and NCS34 neuronal-like cells (Bowerman
et al., 2007; Nolle et al., 2011; Hensel et al., 2014). Of interest is the
interaction of both ROCK and SMNwith profilin IIa (Giesemann
et al., 1999; Da Silva et al., 2003; Sharma et al., 2005; Nolle et al.,
2011), the neuronal isoform of the profilin II gene, which plays
a key role in the control of actin stability (Di Nardo et al., 2000;
Lambrechts et al., 2000). Importantly, the expression and phos-
phorylation of profilin IIa is upregulated in Smn-depleted PC12
cells and at the same time, the amount of ROCK-profilin IIa com-
plex is increased (Bowerman et al., 2007; Nolle et al., 2011). The
interaction between RhoA, ROCK and phosphorylated profilin
IIa has previously been shown to play an inhibitory role on actin-
mediated neuronal outgrowth and differentiation (Da Silva et al.,
2003). A similar augmentation of RhoA-GTP was observed in the
spinal cord of an intermediate SMA mouse model at both pre-
symptomatic and symptomatic stages (Bowerman et al., 2010).
Taken together, these results highlight an increased activity of
the RhoA/ROCK pathway in Smn-depleted neuronal cells and
tissue. Seeing as RhoA/ROCK are key regulators of actin dynam-
ics (reviewed in Hall, 1998), the ensuing aberrantly regulated
actin cytoskeleton may hinder neuronal outgrowth, differentia-
tion and/or plasticity of SMN-depleted neurons (Figure 1).
POTENTIAL BENEFITS OF ROCK INHIBITION ON NEURONAL CELLS
When treated with a ROCK inhibitor (Y-27632 or Fasudil),
the lifespan of an intermediate SMA mouse model is dramati-
cally increased (Bowerman et al., 2010, 2012b). Since levels of
Smn protein and mRNA are unchanged by these pharmacolog-
ical compounds, we can presume that the observed effects are
directly due to the inhibition of the ROCK pathway itself and
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FIGURE 1 | RhoA/ROCK molecular and functional targets in affected
SMA cells and tissues. ROCK acts in a variety of cells and tissues via
several downstream effectors, of which some are known and described
herein (orange boxes) and subsequently linked to the associated cellular
process (purple boxes). Cofilin, profilin and LIMK regulate neuronal outgrowth
and differentiation as well as NMJ plasticity. Cofilin, profilin and myogenin
mediate the effect of RhoA in muscle. In glial cells, the downstream effectors
of the RhoA/ROCK pathway have yet to be defined. Cardiac physiology and
function is in part influenced by myosin phosphatase (MYPT1) and myosin
light chain 2 (MLC2). Both proteins regulate stress fiber formation and cardiac
contraction. Finally, the molecular intermediates in the regulation of glucose
and fatty acid metabolism have yet to be elucidated.
not to an indirect impact on the expression of Smn. Moreover,
the treatment of SMA mice with Y-27632 and Fasudil did not
induce an increase in the number of surviving motoneurons, sug-
gesting that the beneficial effects of ROCK inhibitors are most
likely on improving the health and function of the remaining
motoneurons, but not on preventing the SMN-dependent NMJ
denervation and subsequent axonal and neuronal loss.
At a molecular level, there is a reduction of p-LIMK and p-
cofilin, downstream effectors of ROCK (Maekawa et al., 1999;
Sumi et al., 1999), in SMA mice treated with ROCK inhibitors
(Bowerman et al., 2010, 2012b). Decreased levels of p-LIMK and
p-cofilin could hence create a favorable environment to correct
the existing actin polymerization imbalance. Despite the fact that
profilin IIa levels were not assessed in the spinal cord of SMA
mice treated with ROCK inhibitors, we can hypothesize a similar
effect on profilin IIa to the ones reported for LIMK and cofilin.
Since ROCK is known to form a complex with profilin IIa (Da
Silva et al., 2003), we can also propose that inhibition of ROCK
decreases levels of profilin IIa-ROCK complex, thus allowing for
a more plastic actin cytoskeleton (Figure 2).
While inactivation of the ROCK pathway promotes neuronal
outgrowth and differentiation as well as guidance (reviewed in
Hall, 1998; Mueller, 1999), previous studies have shown that in
SMA mice, motoneurons adequately reach and innervate their
muscle target (Murray et al., 2008; Ling et al., 2012). A recent
report however, suggests that Smn-depleted axons have a reduced
remodeling capacity following injury (Murray et al., 2013). Thus,
ROCK inhibition in SMA mice may increase actin plasticity in
nerve terminals, therefore improving their adaptive ability during
the neurodegenerative process and therefore increasing the main-
tenance of functional NMJs (Figure 2). Moreover, as mentioned
above, treatment with ROCK inhibitors decreases expression of
p-LIMK in spinal cord of SMA mice (Bowerman et al., 2010).
This kinase is known to play a role at the NMJ, suppressing synap-
tic sprouting and growth (Ang et al., 2006). The downregulation
of p-LIMK following inhibition of the ROCK pathway could
therefore improve the plasticity of pre-synaptic NMJ terminals.
However, this does not appear to be the case as analysis of NMJs
from Fasudil-treated SMA mice reveals that ROCK inhibition
does not improve pre-synaptic pathology such as neurofilament
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FIGURE 2 | Proposed model of how systemic ROCK inhibition in SMA
mice may result in beneficial effects within several cells and tissues.
When SMN is depleted, the activity of the RhoA/ROCK pathway is increased
which leads to several cellular defects (described in the green boxes). Upon
systemic ROCK inhibition, these aberrant pathways are ameliorated in
neurons, muscle, glial cells, heart and pancreas (blue boxes). The known or
putative molecular intermediates responsible for mediating the
improvements are cited in the yellow boxes.
accumulation and denervation (Bowerman et al., 2012b). Then
again, the effect of decreased p-LIMK on synaptic sprouting and
growth may be slow yet still beneficial over time, eventually
leading to the occurrence of completely normal NMJs in aging
Fasudil-treated SMA mice (Bowerman et al., 2012b).
SKELETAL MUSCLE
RhoA/ROCK, MUSCLE PHYSIOLOGY AND SMA
Muscle weakness and atrophy are also principal pathologi-
cal SMA hallmarks. Several studies using C2C12 myoblast-like
cells (Shafey et al., 2005), conditional knockout mouse models
(Cifuentes-Diaz et al., 2001; Nicole et al., 2003) as well as human
and murine primary myoblast cultures (Arnold et al., 2004; Boyer
et al., 2014) have highlighted an intrinsic role for Smn inmyoblast
fusion and proliferation as well as in the correct formation of
myotubes.
In muscle, the RhoA/ROCK pathway is required for proper
muscle contraction and function (Formigli et al., 2004) as well
as skeletal myogenesis (reviewed in Bryan et al., 2005). While to
date no study has assessed the expression of RhoA and ROCK
in SMA muscle, the impact of Smn depletion on the expression
of downstream effectors of ROCK has been assessed. Indeed, the
expression of the muscle-specific p-cofilin 2 (Ono et al., 1994) is
increased in the tibialis anterior (TA) of SMA mice (Bowerman
et al., 2012b), suggesting that the RhoA/ROCK pathway could
also be misregulated in this tissue. Cofilin is an actin-binding pro-
tein, which disassembles actin filaments when in its active non-
phosphorylated form (reviewed in Mizuno, 2013). Upregulation
of active cofilin could thus affect actin polymerization, promoting
the more stable filamentous (F) form of actin, and subsequently
affecting muscle physiology and function (Figure 1). However,
the hypothesis for a ROCK-dependent misregulation of p-cofilin
2 in SMA muscle does require further exploration since other
proteins can activate the LIMK-cofilin 2 pathway (reviewed in
Maciver and Hussey, 2002).
POTENTIAL BENEFITS OF ROCK INHIBITION ON SKELETAL MUSCLE
When ROCK inhibitors were administered to an intermedi-
ate SMA mouse model, several prominent modifications at the
muscular level were observed (Bowerman et al., 2010, 2012b).
Indeed, administration of Fasudil and Y-27632 lead to increased
TA myofiber size and NMJ endplate area as well as improved
morphological maturity, without any influence on motoneuron
number. These results suggest that the positive effects of ROCK
inhibitors may not be mediated by motoneurons but by the
muscle itself. It is interesting to note that this gain in muscle
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myofiber size was not correlated with an increase in overall
weight. However, such a phenomenon has already been described
in other cases of muscle atrophy or hypertrophy (Rehfeldt et al.,
2005; Knapp et al., 2006; Kraemer and Vladimir, 2006). Despite
this absence of weight gain, mice treated with ROCK inhibitors
still display a significant improvement in survival, suggesting that
modulation of intrinsic muscle parameters such as expression of
myogenic regulatory factors and actin-dependent regulation of
myogenesis, is sufficient to ameliorate disease progression in SMA
mice (Figure 2).
Cofilin is not the only RhoA/ROCK-dependent misregulated
protein in SMA mouse muscle. Myogenin is a muscle-specific
transcription factor, member of the MyoD family and required
for fusion of myogenic precursor cells during myogenesis (Hasty
et al., 1993). Interestingly, myogenin is upregulated in skele-
tal muscle of SMA mice as well as in Smn-depleted primary
myoblasts (Bowerman et al., 2012b; Boyer et al., 2014; Bricceno
et al., 2014). As active RhoA has been shown to positively con-
trol the expression of myogenin (Takano et al., 1998; Dhawan
and Helfman, 2004), we could hypothesize that the increased
expression of myogenin is a consequence of the upregulated
RhoA/ROCK pathway in SMA muscle. This could explain the
myoblast fusion defects observed in patient- and mouse-derived
Smn-depleted myoblasts and Smn C2C12 cells (Arnold et al.,
2004; Shafey et al., 2005; Boyer et al., 2014). At a molecular level,
by returning the expression of myogenin to physiological levels,
ROCK inhibition could promote normal muscle development,
thus explaining the improvement in myofiber size.
As discussed earlier, the administration of ROCK inhibitors
to SMA mice dramatically increases myofiber and NMJ end-
plate area (Bowerman et al., 2010, 2012b). It has therefore been
suggested that this amelioration in post-synaptic morphology
could have a positive effect on the ensuing synaptic connec-
tion (reviewed in Sanes and Lichtman, 1999), hence protecting
the surviving motoneurons. Further, the modulation of actin
dynamics by ROCK inhibition could have an effect on acetyl-
choline receptor clustering, which is a crucial actin-dependent
step for correct NMJ formation (Dobbins et al., 2006; Cartaud
et al., 2011). Taken together, these observations raise the possi-
bility that while improving skeletal muscle and NMJ parameters,
ROCK inhibition could also positively affect the function of the
remaining motoneurons. Conversely, the overall benefit of ROCK
inhibition in SMA mice may result from the combinatory effects
in neuron and muscle, resulting in an improved communication
and maintenance via the NMJ.
GLIAL CELLS
RhoA/ROCK, GLIAL CELLS AND SMA
Glial cells such as astrocytes, microglia and Schwann cells are
essential to maintain functional homeostasis within the nervous
system as they provide physical support for neurons and secrete
trophic factors important for neuronal health (reviewed in Fields
and Stevens-Graham, 2002; Allen and Barres, 2009). Conversely,
they can also contribute to the neurodegenerative process when
they become aberrantly activated (reviewed in Ilieva et al., 2009).
While limited, previous studies have identified glial cell
abnormalities in SMA patients and mouse models as well as in
Smn-depleted cell lines (reviewed in Papadimitriou et al., 2010).
Indeed, neuroinflammatory gliosis was observed in post-mortem
CNS samples from SMA patients (Araki et al., 2003; Garcia-
Cabezas et al., 2004; Kuru et al., 2009) with the specific occurrence
of reactive astrocytic protrusions, termed glial bundles (Ghatak,
1983; Kuru et al., 2009). Astrocytic activation also occurs in the
early stages of disease progression in the spinal cord of severe
SMA mice (McGivern et al., 2013; Tarabal et al., 2014). In fact,
their cell bodies are enlarged, present an excessive expression of
GFAP and develop thick and short processes (McGivern et al.,
2013). In addition, the presence of activated microglia has been
noted in proximity of motoneurons in the ventral horn area of
the spinal cord of severe SMA mice (Ling et al., 2010; Tarabal
et al., 2014). Finally, myelinating Schwann cells and nerve cap-
ping terminal Schwann cells also display intrinsic defects in SMA
mice. A recent analysis of severe SMAmice has demonstrated spe-
cific hypomyelination in the proximal intercostal nerve, which
innervates pathologically-affected muscles (Hunter et al., 2014).
Furthermore, this study reveals that primary Schwann cells iso-
lated from SMA mice have a reduced ability to myelinate healthy
axons as well as aberrantly express important myelin proteins
such as myelin protein zero (MPZ) and peripheral myelin protein
22 (PMP22). In addition to defects within myelinating Schwann
cells, there is a loss of nerve capping terminal Schwann cells
at the NMJs of intermediate SMA mice (Murray et al., 2013)
that might suggest a defect in migration of Schwann cells to the
endplate. While we cannot exclude the fact that Smn depletion
may simply reduce the survival of terminal Schwann cells, the
former hypothesis is of interest since Smn-depleted astroglioma
U897MG cells display a RhoA/ROCK-dependent delay in migra-
tion (Caraballo-Miralles et al., 2012). Indeed, these cells express
significantly more activated RhoA and downstream effectorMLC.
Further, the delayed migration in Smn-depleted U897MG cells
is reversed by Y-27632, suggesting that the defect is dependent
on the RhoA/ROCK pathway. The caveat of this study is that it
was performed in a cell line and to date, there is no evidence
of glial migration abnormalities in in vivo models of SMA or in
primary cultures of Smn-depleted astrocytes and Schwann cells.
Nevertheless, the studies on U897MG cells and nerve capping
terminal Schwann cells (Caraballo-Miralles et al., 2012; Murray
et al., 2013) raise the possibility that RhoA/ROCK-dependent
glial cell migration is affected in SMA, thus warranting further
examination of this aspect in future investigations.
POTENTIAL BENEFITS OF ROCK INHIBITION ON GLIAL CELLS
As discussed above, myelination and migration defects are
apparent features of SMA glial cells. Interestingly, migration of
Schwann cells along the axon is a necessary step that precedes
myelinating events (reviewed in Bradl and Lassmann, 2010).
Various studies have demonstrated that an activated RhoA/ROCK
pathway is a key inhibitor of Schwann cell migration (Yamauchi
et al., 2004; Wang et al., 2013). Thus, systemic administration
of Y-27632 or Fasudil to SMA mice may improve Schwann
cell migration, subsequently enhancing the myelination poten-
tial of Schwann cells and/or adequate nerve capping at the
NMJ. Indeed, the migration delay in Smn-depleted U897MG
astroglioma cells is corrected following treatment with Y-27632
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(Caraballo-Miralles et al., 2012). Alternatively, treating primary
dorsal root ganglion (DRG) cultures with Y-27632 promotes neu-
rite outgrowth in a Schwann cell-dependent fashion (Fuentes
et al., 2008). Seeing as pre-synaptic NMJ terminals of SMA mice
display aberrant remodeling abilities following paralysis (Murray
et al., 2013), the combination of improved Schwann cell migra-
tion and neuronal outgrowth may explain the specific ameliora-
tion of NMJ pathology observed in Y-27632- and Fasudil-treated
SMA mice (Bowerman et al., 2010, 2012b). Thus, given the gen-
eral importance of glial cells for neuronal maintenance, ROCK
inhibition, by enhancing both the migration and the myelination
of glial cells, could positively affect the function of the surviving
motoneurons (Figure 2).
To date, the few references about an astrocytic phenotype in
SMA reveal reactive glial bundles in the CNS of SMA patients
(Ghatak, 1983; Kuru et al., 2009) as well as activated astrocytes
in severe SMA mice during early symptomatic stages (McGivern
et al., 2013; Tarabal et al., 2014). Analysis of primary astrocyte
cultures shows that RhoA inactivation is necessary and suffi-
cient to induce stellation (Ramakers and Moolenaar, 1998), an
actin-dependent morphology representative of in vivo astrocytes.
Furthermore, treatment of astrocytes with an inhibitor of ROCK
(similar to Y-27632) promotes astrocytic stellation (Abe and
Misawa, 2003). Administering the Y-27632 or Fasudil compounds
to SMA mice may therefore modify the actin cytoskeleton of
abnormally activated astrocytes, rendering them less inflamma-
tory. It is important to note however, that the above-mentioned
experiments on astrocyte stellation were on wild type and in
in vitro astrocyte cultures. We thus cannot clearly say how the
morphology of activated and in vivo astrocytes responds to ROCK
inhibition. In addition to morphological changes, Fasudil and
Y-27632 also increase glutamate transport in primary astrocyte
cultures (Lau et al., 2011). This observation is of interest as defects
in glutamate transport have previously been reported in Type 1
SMA patients (Hayashi et al., 2002). Hence, ROCK inhibition
could also improve astrocytic uptake of glutamate and as result,
reduce glutamate excitoxicity (reviewed in Sattler and Rothstein,
2006).
In microglia, increased activation of the RhoA/ROCK path-
way is linked to a reactive phenotype that hinders regeneration
following injury. Indeed, inhibition of RhoA signaling in rats
following spinal cord injury significantly improves functional
recovery (Dergham et al., 2002) as well as decreases the num-
ber of RhoA-positive microglia at the site of the lesion (Schwab
et al., 2004). Interestingly, activated astrocytes can also recruit
reactive microglia by releasing S100 β, a calcium-binding protein
(reviewed in Donato et al., 2009), in the CNS environment, which
subsequently activates the RhoA/ROCK pathway inmicroglia and
promotes their migration (Bianchi et al., 2011). ROCK inhibition
in SMA mice may therefore decrease microgliosis in the spinal
cord, thus reducing their contribution to the neurodegenerative
process.
While RhoA/ROCK signaling clearly regulates astrocytes,
microglia and Schwann cell function (Figure 1), the pathological
activation of this pathway has yet to be specifically investigated
in SMA glial cells. In addition, the impact of ROCK inhibition
on myelination, astrocyte and microglia activation as well as on
glial cell migration was not evaluated in Y-27632- and Fasudil-
treated SMA mice. These informational gaps thus highlight the
need for further exploration of the RhoA/ROCK pathway in glial
cell processes in SMA.
HEART
RhoA/ROCK, HEART PHYSIOLOGY AND SMA
An important number of reports show that SMA patients present
cardiac defects such as arrhythmias or cardiomyopathy, with the
most common reported myopathies being atrial and ventricular
septum defects and dilated right ventricle (Moller et al., 1990;
Burglen et al., 1995; Menke et al., 2008; Rudnik-Schoneborn
et al., 2008). Indeed, a study of 63 Type 1 SMA patients revealed
that 24% of them presented severe bradycardia (Bach, 2007).
Whether these defects are due to impairment of the autonomous
nervous system or to cardiomyopathy is presently unknown.
Nevertheless, seeing as a significant proportion of SMA patients
develop cardiac abnormalities, various groups have evaluated
heart pathology in SMA mouse models (Bevan et al., 2010; Heier
et al., 2010; Shababi et al., 2010). These independent investiga-
tions have found that severe SMA mice display bradyarrhytmia, a
lower heart rate, a decreased sympathetic tone, a decreased inter-
ventricular septum (IVS) width and an enlargement of the left
ventricular septum as well as interstitial fibrosis due to oxidative
stress. Specific oxidative stress mediators such as angiotensin II
and the nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase (Sowers, 2002) are also increased in the hearts of
severe SMA mice (Shababi et al., 2010, 2012). Concomitantly,
the heart myofibers of SMA mice are disorganized, which
could also explain the physiological cardiac defects described
herein.
Cardiomyocytes express RhoA and ROCK and this pathway
is involved in normal health and function of the heart as well
as in cardiovascular diseases (reviewed in Surma et al., 2011)
(Figure 1). Indeed, the ROCK signaling cascade, via MYPT1 and
MLC2, is involved in stress fiber formation (Amano et al., 1996;
Surma et al., 2011). Activation of ROCK also contributes to fibro-
sis, as Rock1−/− mice do not develop ischemia-induced fibrosis
(Haudek et al., 2009). Moreover, treating mice with Fasudil
inhibits the fibrosis that follows myocardial infarction (Hattori
et al., 2004) or constriction of the transverse aorta (Li et al., 2012).
The influence of ROCK on fibrosis may be through angiotensin II,
as this oxidative stress effector activates the RhoA/ROCK pathway
in cardiomyocytes (Aoki et al., 1998). In regards to the regula-
tion of cardiac hypertrophy, a link has been established between
ROCK and left ventricular remodeling after myocardial infarction
(Hattori et al., 2004) while a study of hypertensive patients with
left ventricular hypertrophy reveals that these patients display an
increased ROCK activity (Gabrielli et al., 2014). Finally, given that
MLC is a substrate of ROCK and that it controls smooth mus-
cle contraction (reviewed by Tsukamoto and Kitakaze, 2013), it
would appear evident that the RhoA/ROCK pathway plays a role
in cardiac contraction. However, to our knowledge, there is yet
to be a study of the impact of ROCK activation and/or inactiva-
tion on contractile properties of the heart. One study though has
reported increased cardiac contraction following ROCK inhibi-
tion in diabetic rats (Lin et al., 2007). Taken together, these known
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functions of RhoA and ROCK in the heart may underlie some of
the cardiac defects observed in SMA patients and mice.
POTENTIAL BENEFITS OF ROCK INHIBITION ON CARDIOMYOCYTES
The beneficial effect of ROCK inhibition in SMA mice could, at
least in part, be due to its effect on cardiac physiology (Figure 2).
Previous therapeutic assessments have in fact demonstrated that
overall ameliorations in lifespan and typical pathological hall-
marks are also accompanied by improved cardiac parameters
(Bevan et al., 2010; Shababi et al., 2012).
As discussed above, there is important oxidative stress, fibro-
sis and hypertrophy within the hearts of SMA mice (Bevan
et al., 2010; Heier et al., 2010; Shababi et al., 2010, 2012).
Further, seeing as these cardiac components can all be modu-
lated by the RhoA/ROCK pathway (reviewed in Surma et al.,
2011), the systemic targeting of ROCK activity in SMA mice
could therefore diminish stress fiber formation, fibrosis and
size of the left ventricle, thus improving overall cardiac health
and function. Indeed, inactivation of ROCK via angiotensin
II inhibition prevents stress fiber formation and hypertrophy
in a cell line derived from rat heart myoblasts (Kim et al.,
2013). Finally, the role of Fasudil as a potent vasodilator
(Fukumoto et al., 2005) may also alleviate the fibrosis-dependent
vasoconstriction of SMA hearts (reviewed in Wright et al.,
2008).
While it is tempting to hypothesize that overexpression of acti-
vated RhoA/ROCK during SMA pathogenesis is responsible for
the observed cardiac defects, assessment of this pathway in SMA
hearts and evaluation of the effects of Y-27632 and Fasudil on
cardiac function and pathology have unfortunately not been per-
formed. In addition, since heart abnormalities appear to only
occur in severe SMA mouse models and Type 1 patients (Menke
et al., 2008), the exact contribution of cardiac dysfunction to SMA
disease progression remains unclear and warrants further inves-
tigation. Thus, systemic ROCK inhibition may positively alter
cardiac function of SMAmice without any direct repercussion on
overall survival.
PANCREAS AND GLUCOSE HOMEOSTASIS
RhoA/ROCK, PANCREAS, GLUCOSE METABOLISM AND SMA
Over the years, an accumulating number of studies have reported
metabolism defects in SMA patients, which mostly concern glu-
cosemetabolism (Lamarca et al., 2013), and fatty acidmetabolism
(Quarfordt et al., 1970; Dahl and Peters, 1975; Tein et al., 1995;
Crawford et al., 1999). More recently, glucose metabolism and
pancreatic abnormalities were uncovered in an intermediate SMA
mouse model and Type 1 SMA patients such as a dramatic
predominance of glucagon-producing α cells at the expense of
insulin-producing β cells within pancreatic islets, fasting hyper-
glycemia, hyperglucagonemia, glucose resistance and increased
hepatic insulin sensitivity (Bowerman et al., 2012c). Further,
a subset of these pathologies are found in a metabolically-
challenged and aging hypomorphic Smn-depleted mouse model
that does not display a canonical SMA pathology (Bowerman
et al., 2014).
RhoA/ROCK signaling modulates various pathways responsi-
ble for pancreatic function and glucose homeostasis (Figure 1).
For example, ROCK regulates important parameters of pancre-
atic β cell function, as treating primary rats β cells with the ROCK
inhibitors H-1152 or Y-27632 results in a glucose-independent
re-organization of actin cytoskeleton and improved glucose-
stimulated insulin secretion (Hammar et al., 2009). Inhibition
of the ROCK pathway also increases the proliferation of human
pancreatic β cells (Aly et al., 2013) as well as promotes insulin pro-
moter activity and insulin expression in β cell-derived HIT-T15
cells (Nakamura et al., 2006). In addition to a role in pancreatic
β cell function, use of a dominant negative ROCK in L6 mus-
cle cells shows that blocking this kinase significantly reduces the
insulin-induced glucose transport in myotubes (Furukawa et al.,
2005). This study further demonstrated that overexpression of
ROCK is sufficient to enhance insulin signaling and response
to insulin stimulation in 3T3-L1 adipocytes, L6 myotubes and
CHOIR/IRS−1 cells [CHO cells expressing insulin receptor (IR)
and insulin receptor substrate 1 (IRS1)] through phosphory-
lation of IRS1. All together, these observations point to a key
regulatory role for the RhoA/ROCK pathway in specific pancre-
atic functions as well as in the general maintenance of glucose
homeostasis.
POTENTIAL BENEFITS OF ROCK INHIBITION ON PANCREATIC AND
GLUCOSE METABOLISM FUNCTION
To date, nothing is known about the effect of SMN deple-
tion on the pancreatic RhoA/ROCK pathway and how it could
contribute to SMA pathology. However, beneficial therapeutic
strategies evaluated in SMA mice such as muscle-specific insulin-
like growth factor 1 (IGF1) administration, neuronal depletion
of phosphatase and tensin homolog (PTEN) and systemic tri-
chostatin A administration have previously been shown to also
influence glucose metabolism (Di Cola et al., 1997; Ranke, 2005;
Stiles et al., 2006; Avila et al., 2007; Sun and Zhou, 2008; Ning
et al., 2010; Bosch-Marce et al., 2011). Systemic ROCK inhibition
in SMA mice may therefore partially or completely restore secre-
tion of insulin and glucagon by pancreatic cells, glucose tolerance,
insulin sensitivity as well as storage of glucose by muscles. Indeed,
improvement of the crucial insulin-dependent muscle glucose
uptake (reviewed in Huang and Czech, 2007) may explain the
significant improvements in skeletal muscle and NMJ pathology
observed in Y-27632- and Fasudil-treated SMA mice (Bowerman
et al., 2010, 2012b). Alternatively, the positive effect of ROCK
inhibition could be directly achieved through pancreatic mod-
ulation as inactivation of the ROCK pathway enhances β cell
proliferation, insulin expression and glucose-stimulated insulin
secretion (Nakamura et al., 2006; Hammar et al., 2009; Aly et al.,
2013). However, these results were obtained in β cell cultures
and whether systemic inhibition of ROCK would have the same
effects in vivo still needs to be evaluated. In the same manner, the
observation that ROCK enhances insulin signaling and glucose
storage in muscle cell lines should be verified in animal models.
Lastly, it has been reported that β cell proliferation is modu-
lated by an interaction between CREB, a transcription factor
that mediates hepatic glucagon signaling (reviewed in Quesada
et al., 2008; Altarejos andMontminy, 2011), and the RhoA/ROCK
pathway (Aly et al., 2013). Combined with the recent obser-
vation that hepatic p-CREB signaling is increased in various
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Smn-depleted mouse models (Bowerman et al., 2014), these find-
ings strongly support the assessment of the RhoA/ROCK path-
way in all SMA tissues (pancreas, liver, muscle) that coordinate
glucose homeostasis.
CONCLUSION AND PERSPECTIVES
While SMA is undeniably primarily a motoneuron disease, a
growing number of studies have reported defects in other cell
types and organs, whether they be within the CNS such as
glial cells, or outside, like the pancreas, heart or skeletal muscle
(reviewed in Hamilton and Gillingwater, 2013). The development
of systemic therapeutic approaches such as ROCK inhibition has
further emphasized the need to further understand the contri-
bution of multiple cell types in this pathology. In the present
review, we have described the known roles of the RhoA/ROCK
pathway in several cells and organs that have previously been
reported to be affected in SMA cellular and mouse models as
well as in patients (Figure 1). We have further hypothesized how
systemic ROCK inhibition could influence each particular cell
and/or tissue eventually impacting disease progression in SMA
mice (Figure 2).
In neuronal cells, the primary cell type affected in SMA,
inhibiting ROCK could render neuronsmore plastic, thus permit-
ting a better maintenance of functional NMJs. Skeletal muscle for
its part, is also an important tissue proven to play both intrinsic
and extrinsic roles in SMA pathology (reviewed in Boyer et al.,
2013). ROCK inhibition in skeletal muscle could help restore
normal myogenesis and developmental programs. Astrocytes,
microglia and Schwann cells are essential glial cells required
for the proper maintenance of CNS homeostasis (reviewed in
Fields and Stevens-Graham, 2002; Allen and Barres, 2009) and
recent studies suggest that they may be aberrantly regulated in
SMA. Indeed, SMA glial cells show impairedmyelinating capacity,
decreased migration, increased activation and reduced number at
the NMJ (Caraballo-Miralles et al., 2012; McGivern et al., 2013;
Murray et al., 2013; Hunter et al., 2014; Tarabal et al., 2014), all
of which could be ameliorated following systemic ROCK inhi-
bition. SMA patients and mouse models also display important
cardiac defects such as oxidative stress, fibrosis and hypertro-
phy (Moller et al., 1990; Burglen et al., 1995; Bach, 2007; Menke
et al., 2008; Rudnik-Schoneborn et al., 2008; Bevan et al., 2010;
Heier et al., 2010; Shababi et al., 2010), pathological events con-
trolled by the RhoA/ROCK pathway (reviewed in Surma et al.,
2011). ROCK inhibition could therefore have a positive effect on
overall cardiac physiology and function in SMA mice. Finally,
SMA patients and mice show defects in glucose and fatty acid
metabolism as well as in pancreatic islet development (Quarfordt
et al., 1970; Dahl and Peters, 1975; Tein et al., 1995; Crawford
et al., 1999; Bowerman et al., 2012c, 2014; Lamarca et al., 2013).
Given that the RhoA/ROCK pathway enhances β cell prolifera-
tion, insulin expression, glucose-stimulated insulin secretion and
glucose uptake in muscle cells (Furukawa et al., 2005; Nakamura
et al., 2006; Hammar et al., 2009; Aly et al., 2013), treatment
of SMA mice with ROCK inhibitors may modulate key glucose
homeostasis pathways.
It thus appears that it has become insufficient to limit our eval-
uation of therapeutic approaches for SMA to neuronal function
and pathology. While SMA remains a canonical neurodegen-
erative disease, it is becoming more and more evident that a
convergence of multiple pathways, including RhoA/ROCK, in
various cells and tissues within or outside the CNS, influence
SMA pathogenesis and have to be taken in account when assessing
the beneficial effects of systemically-delivered pharmacological
compounds.
Of both Y-27632 and Fasudil, only Fasudil has been approved
for evaluation in clinical trials for disorders such as Raynaud’s
Phenomenon, atherosclerosis and amyotrophic lateral sclerosis
(ALS), a motoneuron pathology closely related to SMA (reviewed
in Achsel et al., 2013). This is of further relevance due to the recent
identification of mutations within the Profilin 1 gene in ALS
patients (Wu et al., 2012), highlighting profilin, a downstream
effector of ROCK, as a common pathological player in both ALS
and SMA. However, to our knowledge, there are currently no
planned clinical trials of Fasudil for SMA patients. One of the rea-
sons may be the potential toxicity of this compound in younger
animals (Momma et al., 2009; Bowerman et al., 2012b). For the Y-
27632 study in SMA mice, a low (10mg/kg) and high (30mg/kg)
daily dose was based on previous dosing regimens validated in
adult mice following cardiac ischemia/reperfusion injury (Bao
et al., 2004). As for Fasudil in SMA mice, previously validated
low (30mg/kg) and high (100mg/kg) (Fukui et al., 2008) daily
doses were also initially used (Bowerman et al., 2012b). However,
the lower dose proved to have no effect, most likely due to its
short half-life and rapid metabolization (Satoh et al., 2001), while
the higher dose was lethal in neonatal pups, probably because of
Fasudil’s role as a potent vasodilator (Fukumoto et al., 2005). In
an attempt to both maximize the activity of Fasudil and reduce its
toxicity, an escalating dosing regimen (30mg/kg twice daily from
post-natal day (P) 3 to P6; 50mg/kg twice daily from P7 to P13;
75mg/kg twice daily from P14 to P21) was administered to SMA
mice (Bowerman et al., 2012b). This however, also led to a non-
negligible lethality. Thus, an intermediate dose of 30mg/kg twice
daily was finally evaluated, which resulted in the beneficial effects
described herein. Seeing as SMAmostly affects children under the
age of two (Crawford and Pardo, 1996), the reported toxicity of
Fasudil (Bowerman et al., 2012b; Momma et al., 2009) will have
to be seriously taken into account when establishing a clinical trial
of ROCK inhibitors for SMA patients. The recently started clini-
cal trial of Fasudil for ALS patients is nevertheless at step forward
for the therapeutic assessment of ROCK inhibitors in neurode-
generative diseases and will, without a doubt, help pave the path
for similar endeavors in SMA.
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